Alice T. Shaw, MD, PhD | Authors

June 19, 2017

Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.

February 27, 2014

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer

January 03, 2014

Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.

November 25, 2013

Alice T. Shaw, MD, PhD, discusses using crizotinib to treat patients with ALK-positive lung cancer.